Article PDF first page preview

First page of Gender perspective in Lung Neuroendocrine Tumors: a critical review

Background: The role of gender has gained attention in oncology. In the setting of lung neuroendocrine tumors (L-NETs) the existence of differences between male and females has been suggested, but no clear-cut data are available. We aim to provide a critical analysis of the existing literature regarding sex role in L-NETs. Methods: We performed an extensive search of the available literature to provide a critical narrative review focused on key topics as epidemiology, histopathological and molecular features, functioning syndromes, prognosis and response/toxicity to treatments in L-NETs according to sex. Results: Female patients are more likely to have a L-NET than males. The reasons underlying this gender differences are still unclear; a biologic mechanism for the sex difference is possible, through a role for hormones in regulating gene expression and promoting neuroendocrine cell proliferation. A difference in immunohistochemical biomarkers has been found; thyroid transcription factor‐1 (TTF-1) expression appears to be associated with female gender; at molecular level in the majority of studies L-NET mutational profile is not stratified for sex. In terms of prognosis, a correlation between male gender and a more aggressive disease has been found. Patient’s gender has been recognized as a key modulator in the response/resistance to anticancer treatments, however for L-NETs the available data regarding the activity of different treatments and their toxicities are scarce as in clinical trials designed for L-NETs a stratified evaluation of drugs’ activity according to patients’ sex is largely missing. Conclusions: There is emerging evidence suggesting a gender role in L-NETs, however further studies are needed to better understand the pathogenesis of these tumors and to plan tailored treatments.

Journal Section:
Review Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.